Overall rank by patents
#13,574
of 50,000 tracked assignees
USPTO PatentsView assignee record - 22 granted patents across 9 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
The verdict
According to USPTO PatentsView, New ranks #13,574 of 50,000 tracked US assignees by granted-patent volume, with 22 patents across 9 technology areas.
USPTO PatentsView assignee plate
Corpus R13574 · US Corporation #13,574 · 22 grants
GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Nan Juen International Co., Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
New York Stem Cell F… · this assignee
35 score
3D Lighting Innovati… · lowest
7 score
What this shows New York Stem Cell Foundation, Inc. stamps GRANTS-SMALL, MID-PACK, PHOTO-FINISH, CPC-NARROW, INNOV-THIN, CLAIMS-RICH, TYPE-USCORP, VEL-SURGE, BOOK-FULL. Volume places it #13,574 of 50,000; Innovation Score 35.2/100 sits in the top 50% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Nan Juen International Co., Ltd. (±0 grants).
New York Stem Cell Foundation, Inc. has been granted 22 US utility patents between 2016 and 2025, placing New York Stem Cell Foundation, Inc. at #13,574 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.8 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, New York Stem Cell Foundation, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, New sits between Nan Juen International Co., Ltd. (22 patents, rank #13,576) and Novarad Corporation (22 patents, rank #13,584) - the closest US assignees by grant volume. The composite Innovation Score of 35.2/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 13 grants, compared with 8 in the 2015–2019 window, a +63% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. New York Stem Cell Foundation, Inc.'s 17.8 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 9 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Nan Juen International Co., Ltd.
22 patents
Nanometrics Incorporated
22 patents
NetBase Solutions, Inc.
22 patents
Neuralink Corp.
22 patents
Nexenta Systems, Inc.
22 patents
Next Science IP Holdings Pty Ltd
22 patents
Ningbo Albert Novosino Co., Ltd.
22 patents
Novarad Corporation
22 patents
New York Stem Cell Foundation, Inc.
22 patents
What this shows New holds 22 patents at rank #13,580, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #13,580 in granted patent volume.
Other assignees with the most granted patents in New's primary technology class.
New's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
35 Top 50% higher than 50% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 4.5% |
| 2018 | 1 | 4.5% |
| 2019 | 6 | 27.3% |
| 2020 | 1 | 4.5% |
| 2021 | 6 | 27.3% |
| 2022 | 2 | 9.1% |
| 2023 | 3 | 13.6% |
| 2024 | 1 | 4.5% |
| 2025partial year | 1 | 4.5% |
Top 9 of 9 technology areas
Overall rank by patents
#13,574
of 50,000 tracked assignees
35.2 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.